Skip to content

A Study Evaluating the Clinical Efficacy of Treatment based on Chinese Medicine Guideline in Patients With Myasthenia Gravis

A Study Evaluating the Clinical Efficacy of Treatment based on Chinese Medicine Guideline in Patients With Myasthenia Gravis

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ITMCTR
Registry ID
ITMCTR2100005025
Enrollment
Unknown
Registered
2021-07-06
Start date
2021-07-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myasthenia gravis

Interventions

Sponsors

The Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Age is not limited, gender is not limited; 2.Clinical MG manifestations, and or neostigmine test positive, low frequency repeated electrical stimulation positive, serum AChR, Musk, LRP4, Titin, RyR and other antibodies are positive, clinical diagnosis of myasthenia gravis can be diagnosed; 3.Patients with myasthenia gravis classified as type I, type II (type IIa, type IIb), III (type IIIa, type IIIb) and IV (type IVa, IVb) in clinical MGFA; 4.Agree to participate in this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with severe medical diseases: severe arrhythmia, severe lung disease, ALT/AST> 2 times the normal value, Cr> 2 times the normal value; 2.Patients with malignant tumors (excluding thymoma), history of HIV infection, or severe immunodeficiency; 3.Female patients who are pregnant, breastfeeding or breastfeeding; 4.History of mental illness; 5.Tuberculosis patients with tuberculin test or T-SPOT test positive.

Design outcomes

Primary

MeasureTime frame
Quantitative myasthenia gravis score;

Secondary

MeasureTime frame
Security Index;Myasthenia gravis specific muscle strength test;Analysis of the dosage of other drugs such as cholinesterase inhibitors, glucocorticoids, immunosuppressants, etc.;Myasthenia Gravis Daily Living Scale;Acetylcholine receptor antibody quantitative value;Absolute and relative scores for myasthenia gravis;Myasthenia Gravis Quality of Life Scale;

Countries

China

Contacts

Public ContactWang Jian

The Affiliated Hospital of Changchun University of Traditional Chinese Medicine

jian-w222@163.com+86 15948000772

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026